



Supplementary Figure 1. Concentration-inhibition curves for PSB-12062 and BX-430 using human P2X₄ stable cells, and agonist responses in human P2X₇ stable cells. A) ATP concentration response (0.01 μM – 300 μM) of P2X₄ over-expressing 1321N1 astrocytoma cells ($EC_{50} = 0.12 \pm 0.0031 \mu\text{M}$; N=3). Inhibition curve of P2X₄ antagonist: B) PSB-12062 (0.03 μM – 30 μM; $IC_{50} = 3.31 \pm 0.34 \mu\text{M}$; N=3) and C) BX-430 (0.01 μM – 30 μM; $IC_{50} = 1.56 \pm 0.085 \mu\text{M}$; N=3) on P2X₄ over-expressing 1321N1 astrocytoma cells. D) BzATP concentration response (1 μM – 1 mM) of P2X₇ over-expressing 1321N1 astrocytoma cells ($EC_{50} = 43.4 \pm 7.23 \mu\text{M}$; N=3). E) ATP concentration response (3 μM – 3 mM) of P2X₇ over-expressing 1321N1 astrocytoma cells (no response observed below 3 mM ATP; N=3).



Supplementary Figure 2. Effect of P2X and P2Y receptor antagonists on net Ca²⁺ movement in response to 100 μM ATP in human MDMs. Effect of: A and B) selective P2X₁ receptor antagonist (30 μM Ro0437626; N=4 donors) and C and D) selective P2X₇ receptor antagonist (5 μM A438079; N=4 donors) on net calcium movement and time-response curves of Ca²⁺ response. E) Effect of PLC inhibitor (10 μM U-73122; N=3 donors) on peak magnitude of ATP-evoked Ca²⁺ response. Effect of P2Y selective antagonists on ATP-evoked Ca²⁺ response: F and G) P2Y₁ (1 μM MRS2500, N=3 donors), H and I) P2Y₆ (10 μM MRS2578; N=3 donors), J and K) P2Y₂ (10 μM ARC-118925xx; N=3 donors), L) P2Y₁₁ (NF340; N=3 donors) and M) P2Y₁₃ (MRS2211; N=3 donors), on net calcium movement. Data is represented as normalized area under the curve to ATP response. Statistical significance is represented as * p<0.05, ** p<0.01 and *** p<0.001.



Supplementary Figure 3. Multiplex analysis of IL-10 (N=7 donors), MDC (N=7 donors), IL-8 (N=7 donors), RANTES (N=7 donors) and IL-27 (N=7 donors) under various conditions in human monocyte-derived macrophages.

Antagonist	Calcium response normalized to 100% ATP)		Decay kinetics (τ)	Statistical Significance
	Peak magnitude	Area Under the Curve		
P2X1(30 μM Ro0437626)	131.29 ± 10.26% (N=4)	131.27 ± 23.41% (N=4)		Peak: P < 0.01 AUC: P > 0.05
P2X4(5 μM BX430)	96.21 ± 6.61% (N=5)	42.28 ± 12.65% (N=5)	Vehicle: 21.56 ± 0.88 s. BX430: 16.605 ± 0.55 s.	Peak: P > 0.05 AUC: P < 0.05
P2X4(10 μM PSB-12062)	92.34 ± 7.71% (N=12)	61.03 ± 7.49% (N=12)	Vehicle: 6.52 ± 3.17 s. PSB-12062: 28.06 ± 1.47 s.	Peak: P < 0.05 AUC: P < 0.01
P2X7(10 μM A438079)	112.77 ± 11.10% (N=4)	101.17 ± 22.20% (N=4)		Peak: P > 0.05 AUC: P > 0.05
P2Y1(1 μM MRS2500)	85.28 ± 7.66% (N=3)	100.55 ± 5.32% (N=3)		Peak: P > 0.05 AUC: P > 0.05
P2Y2(10 μM ARC-118925xx)	86.45 ± 5.16% (N=3)	93.97 ± 7.77% (N=3)		Peak: P > 0.05 AUC: P > 0.05
P2Y6(10 μM MRS2578)	73.85 ± 7.11% (N=3)	132.69 ± 7.73% (N=3)		Peak: P > 0.05 AUC: P > 0.05
P2Y11(10 μM NF340)	79.48 ± 3.20% (N=3)	106.14 ± 13.74% (N=3)	Vehicle: 22.03 ± 3.17 s. NF340: 22.64 ± 7.70 s.	Peak: P > 0.05 AUC: P > 0.05
P2Y13(10 μM MRS2211)	69.59 ± 5.56% (N=3)	58.26 ± 2.20% (N=3)	Vehicle: 22.03 ± 3.17 s. MRS2211: 25.17 ± 3.92 s.	Peak: P > 0.05 AUC: P < 0.01
P2Y11(NF340) + P2Y13(MRS2211)	54.12 ± 2.29% (N=3)	77.47 ± 16.62% (N=3)		Peak: P > 0.05 AUC: P > 0.01
P2X4(BX430) + P2Y11(NF340) + P2Y13(MRS2211)	48.27 ± 2.85% (N=4)	68.2 ± 2.63% (N=4)		Peak: P < 0.05 (against NF340 + MRS2211) AUC: P < 0.05
P2X4(PSB-12062) + P2Y11(NF340) + P2Y13(MRS2211)	53.52 ± 2.95% (N=4)	78.3 ± 6.56% (N=4)		Peak: P > 0.05 (against NF340 + MRS2211) AUC: P > 0.05

Supplementary Table 1. Effect of P2 receptor antagonists on the magnitude, shape (area under the curve), and decay kinetics (τ) of 100 μ M ATP-evoked Ca^{2+} responses in human MDMs. Data is represented as normalized values to either 100% peak magnitude or 100% area under the curve of 100 μ M ATP- Ca^{2+} response. Contribution of receptor activation towards shape of ATP-evoked Ca^{2+} response is assessed through measurements of decay kinetics as obtained through τ value. Decay kinetic values are represented in seconds (s). Statistical significance is represented for each measurement with P>0.05 indicating non-significant change to vehicle data.